With a Median Post-Transplantation Follow-Up of 34.6 Months, There was No Significant Difference in Time to Engraftment, Acute GVHD, Event-Free Survival, or Overall Survival. Yakoub-Agha I, Mesnil F, Kuentz M, et al; French Society of Bone Marrow Transplantation and Cell Therapy. Allogeeic marrow stem-ce transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006;24:5695- 02. Reprinted with permission from the American Society of Clinical Oncology.

With a Median Post-Transplantation Follow-Up of 34.6 Months, There was No Significant Difference in Time to Engraftment, Acute GVHD, Event-Free Survival, or Overall Survival. Yakoub-Agha I, Mesnil F, Kuentz M, et al; French Society of Bone Marrow Transplantation and Cell Therapy. Allogeeic marrow stem-ce transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006;24:5695- 02. Reprinted with permission from the American Society of Clinical Oncology.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal